Transition to Subcutaneous Immune Globulin 16.5% Improves Patient-Reported Quality of Life

SUGAR LAND, TX – (July 1, 2022) Subcutaneous immune globulin (IGSC) is indicated for the treatment of primary immunodeficiences (PID) and offers the convenience of self-administration, fewer systemic reactions, and more stable IgG levels compared to intravenous IG (IVIG).  The Life Quality Index (LQI) is an instrument to evaluate health-related quality of life (QOL) and treatment satisfaction among patients receiving IG therapy.

In this study, the authors assessed patient-reported health-related QOL in PID patients who transitioned to IGSC 16.5% (Cutaquig®) from IVIG or an alternative IGSC product in a real-world setting.  Using the LQI questionnaire, study authors assessed domains of treatment interference, therapy-related problems, and therapy setting.  The survey was performed on all IG-experienced patients at the time of switching to IGSC 16.5%, then again at 3, 6, and 12 months.

The study included 34 patients with a median age of 58 years and median duration of IG treatment prior to switch of 4.9 years. Thirteen patients were transitioned from IVIG and 21 from another IGSC product.  Individual QOL questions showed improvement over time as well as survey responses by domain.  Patients who transitioned from IVIG to IGSC 16.5% had lower baseline QOL scores and a significantly higher rate of improvement in the treatment interference domain (P<0.05) compared to those with prior IGSC.

The study was the first real-world patient-reported QOL survey in patients receiving IGSC 16.5%, concluding that excellent quality of life was achieved in IG-experienced patients receiving IGSC 16.5%, particularly when transitioning from IVIG.

This study was presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2022 Annual Meeting. For a copy of this research poster study, please call 1.866.654.2451 or email us.


Healix is the premier provider of outpatient infusion management services. Focused on Patient and Physician Peace of Mind for over 30 compassionate years, we offer unparalleled capabilities for optimal patient care, comfort, compliance, and clinical outcomes in an outpatient setting.

The American Academy of Allergy, Asthma & Immunology (AAAAI) is the leading membership organization of more than 7,100 allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. Research presented at the AAAAI Annual Meeting, February 25-28 in Phoenix, Arizona, is published in an online supplement to The Journal of Allergy and Clinical Immunology.

Herrscher R, Langford J, Mehta S, Van Anglen L. Transition to Subcutaneous Immune Globulin 16.5% Improves Patient-Reported Quality of Life. J Allergy and Clin Immunol. 2022 Feb;149(2):AB124. DOI: https://doi.org/10.1016/j.jaci.2021.12.425

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.